IP Library Granted Patent US 8,012,934
Granted Patent B2
US 8,012,934 · App. 10/147,633 · Granted Sep 6, 2011

Small peptides and methods for treatment of inflammation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,012,934
App. No.
10/147,633
Granted
Sep 6, 2011
Kind
B2
Abstract

Methods for treating cutaneous inflammation are described. Also described is a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr.

Claims (3)

1. A method for treating cutaneous inflammation in a mammal, the method comprising administering to the mammal an anti-inflammatory effective amount of a peptide having the formula f-Met-Leu-X where X (SEQ ID NOs: 1, 2 and 3) is selected from the group consisting of Tyr, Tyr-Phe (SEQ ID NO: 1), Phe-Phe (SEQ ID NO: 2) and Phe-Tyr (SEQ ID NO: 3).

2. A method for treating cutaneous inflammation in a mammal, the method comprising administering to the mammal an anti-inflammatory effective amount of a peptide having the formula f-Met-Leu-X where X (SEQ ID NOs: 1, 2 and 3) is selected from the group consisting of Tyr, Tyr-Phe (SEQ ID NO: 1), Phe-Phe (SEQ ID NO: 2) and Phe-Tyr (SEQ ID NO: 3), wherein the cutaneous inflammation is selected from the group consisting of dermatitis, eczema, psoriasis, contact dermatitis, sunburn and aging.

3. The method of claim 1 , wherein another active ingredient is administered with said peptide, said active ingredient being selected from the group consisting of anti-leukotrienes, beta 2 agonists and corticosteroids.